<DOC>
	<DOCNO>NCT00269113</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety standard chemotherapy East German Study Group Hematology Oncology versus standard chemotherapy plus MabThera ( 375mg/m2 iv , monthly 8 cycle ) patient indolent non-Hodgkin 's mantle cell lymphoma . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Advanced Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient &gt; =18 year age ; advanced , lowgrade nonHodgkin 's mantle cell lymphoma . possibility curative radiation therapy ; secondary NHL ; participation another clinical trial eg cytostatic chemotherapy cytokine ; concomitant disease and/or restrict organ function preclude therapy accord study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>